



**Micrima:**  
Redefining cancer diagnostics.

## MARIA<sup>®</sup> Update - Issue 10

You are receiving this newsletter as you have requested to be kept up to date with MARIA<sup>®</sup> developments. Micrima have installed their third MARIA<sup>®</sup> breast imaging system in Leeds NHS Hospitals Teaching Trust and their fourth at Exeter's Health Screening site during December 2021. Micrima also have an additional installation planned for another In Health site for January 2022.

### *Clinical Update*

Unfortunately, data collection was massively effected by COVID, so we are significantly behind where we expected to be in development, due to this delay. We are recruiting from several sites across Europe using our 6<sup>th</sup> Generation MARIA<sup>®</sup> system. These sites are firstly collecting data from symptomatic clinics, with patients receiving a MARIA<sup>®</sup>. All other imaging is being used along with any histopathology, to develop a ground truth. This is being used in development of the classifier to identify possible malignant lesions. The second strand is in screening, which is collecting a MARIA<sup>®</sup> scan and Mammogram with a density score. This is being used to enhance the MARIA<sup>®</sup> density score which is part of the 7<sup>th</sup> Generation system.

The LIESL trial at Royal Marsden has finished recruitment slightly early due to COVID restrictions, with 389 patients and 113 cancers. Initial results have been submitted by the clinicians for ECR 2022, hopefully we should hear if this has been accepted any day now. Gottingen has collected data on 115 patients for us as part of our data collection for machine learning. They are continuing to work with us and will be continuing to collect data in 2022.



The Athens system was installed in the autumn. Dr Lazarou and his team are collecting data for machine learning and for our density work. This will continue in 2022 and we are in discussion with Dr Lazarou about a possible second site. Our system in Leeds has now been installed. The operator has been trained and the plan is to begin recruitment this month. Dr Nisha Sharma is PI at this site and they will be collecting data for machine learning and density work.

We have two in health sites identified for collecting data for the density work from screening sites. The first of these, our fourth site, has been installed in the Exeter screening site and the fifth will be installed in the Romford site in early January.

We aim to collect 1000 data sets from these sites by the middle of 2022. If you are interested in becoming a data collection site for us, please get in touch via email to [info@micrima.com](mailto:info@micrima.com). We will be expanding data collection further in 2022.

## **MARIA<sup>®</sup> 7**

Micrima have developed a 7<sup>th</sup> generation system which includes improvements suggested by radiologists, MARIA<sup>®</sup> operators and patients.

The main developments are:

- Improved Cancer Detection
- MARIA<sup>®</sup> Density Score
- Enhanced User Comfort
- Future Enabled to Accommodate Software Updates

This system has been submitted for CE marking and we are awaiting a response from our approval body.



## ***Clinical Presentations of MARIA<sup>®</sup> 7***

There have been limited opportunities to present at congresses due to COVID since our last newsletter. We have attended the Medical Imaging Conference in Birmingham, UK and have been involved in a number of virtual presentations and podcasts.

Dr Nisha Sharma, Director of Breast Screening and Clinical Lead for breast imaging at Leeds NHS Teaching Hospital Trust, and our Commercial Director, Elizabeth Blake presented at the NHS oncology conference earlier this year. They looked at breast density and its effect on breast cancer. Click the link if you are interested in watching: [NHS Oncology convention Micrima - YouTube](#).



In the summer we launched our podcast, [Breast Cancer: Density Matters](#) and were also featured on [RadCast Podcast](#) with Professor Iain Lyburn talking to RadCast about breast screening and MARIA<sup>®</sup>.

Micrima are expanding their social media reach with the addition of [Instagram](#) and [Facebook](#). The aim of these activities at this stage is to increase awareness of the issues with breast density and the need to look for alternatives, while still supporting the message of attending your mammogram.

If you are interested in arranging an overview of the MARIA<sup>®</sup> technology for your local event, please contact [info@micrima.com](mailto:info@micrima.com).

## Next Update

We look forward to sharing more progress on the new clinical trials as they progress. Please find additional information or previous copies of newsletters on our company [website](#).



---

*Copyright © \*2018 Micrima Limited\*, All rights reserved.*

**Our mailing address is:**  
[info@micrima.com](mailto:info@micrima.com)

Want to change how you receive these emails?  
You can [update your preferences](#) or [unsubscribe from this list](#)